EyePoint Inc Share Price Today: Live Updates & Key Insights

EyePoint Inc share price today is $12.19, up -2.25%. The stock opened at $12.4975 against the previous close of $12.47, with an intraday high of $12.4975 and low of $12.06.

EyePoint Inc Share Price Chart

EyePoint Inc

us-stock
To Invest in {{usstockname}}
us-stock

EyePoint Inc Share Price Performance

$12.19 -0.0225(-2.25%) EYPT at 27 Jul 2026 02:57 PM Biotechnology
Lowest Today 12.06
Highest Today 12.4975
Today’s Open 12.4975
Prev. Close 12.47
52 Week High 19.11
52 Week Low 9.40
Day’s Range: Low 12.06 High 12.4975
52-Week Range: Low 9.40 High 19.11
1 day return -
1 Week return -3.63
1 month return -10.65
3 month return -10.29
6 month return -21.06
1 year return +21.75
3 year return +19.84
5 year return +53.07
10 year return -

EyePoint Inc Institutional Holdings

Suvretta Capital Management, LLC 9.90

Cormorant Asset Management, LLC 9.86

BlackRock Inc 8.57

Federated Hermes Inc 6.77

Franklin Resources Inc 6.02

Vanguard Group Inc 5.75

HHG PLC 4.30

Vanguard Capital Management, LLC 4.25

Adage Capital Partners Gp LLC 3.94

Paradigm Biocapital Advisors LP 3.75

COMMODORE CAPITAL LP 3.37

Federated Hermes Kaufmann Growth 3.31

Federated Hermes Kaufmann R 3.31

Vanguard Total Stock Mkt Idx Inv 3.16

State Street Corp 2.50

iShares Russell 2000 ETF 2.43

Geode Capital Management, LLC 2.37

Federated Hermes Kaufmann Small Cap A 2.37

Federated Hermes Kaufmann Small Cap Grow 2.37

Franklin Biotechnology Discv A(acc)USD 2.29

Citadel Advisors Llc 2.27

Aberdeen Group PLC 2.07

StemPoint Capital LP 1.94

Franklin Small Cap Growth Adv 1.77

Franklin US Small Cap Growth Equity 1.72

Balyasny Asset Management LLC 1.72

Parkman Healthcare Partners LLC 1.62

Eventide Asset Management, LLC 1.49

Eventide Healthcare & Life Sciences I 1.49

abrdn Healthcare Investors 1.46

Franklin Biotechnology Discovery A 1.34

Morgan Stanley - Brokerage Accounts 1.31

Vanguard Institutional Extnd Mkt Idx Tr 1.08

HSBC GIF Glb Eq Sust Hlthcare AC USD 0.99

Fidelity Small Cap Index 0.92

abrdn Life Sciences Investors 0.85

Candriam Eqs L Biotech C USD Cap 0.80

iShares Russell 2000 Growth ETF 0.72

Janus Henderson Hrzn Biotec E2 USD 0.67

State Street® SPDR® S&P® PhrmctlsETF 0.63

EyePoint Inc Market Status

Strong Buy: 9

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

EyePoint Inc Fundamentals

Market Cap 1045.50 M

PB Ratio 4.6018

PE Ratio 0.0

Enterprise Value 858.28 M

Total Assets 364.00 M

Volume 1468697

EyePoint Inc Company Financials

Annual Revenue FY23:42523000 42.5M, FY22:41404000 41.4M, FY21:36939000 36.9M, FY20:34437000 34.4M, FY19:20365000 20.4M

Annual Profit FY23:35479000 35.5M, FY22:33078000 33.1M, FY21:28762000 28.8M, FY20:28613000 28.6M, FY19:17678000 17.7M

Annual Net worth FY23:-100148000 -100.1M, FY22:-124512000 -124.5M, FY21:-63915000 -63.9M, FY20:-52651000 -52.7M, FY19:-62969000 -63.0M

Quarterly Revenue Q1/2026:696000 0.7M, Q3/2025:966000 1.0M, Q2/2025:5333000 5.3M, Q1/2025:24453000 24.5M, Q3/2024:10524000 10.5M

Quarterly Profit Q1/2026:168000 0.2M, Q3/2025:245000 0.2M, Q2/2025:5168000 5.2M, Q1/2025:23648000 23.6M, Q3/2024:9788000 9.8M

Quarterly Net worth Q1/2026:-84832000 -84.8M, Q3/2025:-59732000 -59.7M, Q2/2025:-59426000 -59.4M, Q1/2025:-45195000 -45.2M, Q3/2024:-29361000 -29.4M

About EyePoint Inc & investment objective

Company Information EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 214

Industry Biotechnology

CEO Dr. Jay S. Duker M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

EyePoint Inc FAQs

What is the share price of EyePoint Inc today?

The current share price of EyePoint Inc is $12.19.

Can I buy EyePoint Inc shares in India?

Yes, Indian investors can buy EyePoint Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy EyePoint Inc shares in India?

You can easily invest in EyePoint Inc shares from India by:

Can I buy fractional shares of EyePoint Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of EyePoint Inc?

EyePoint Inc has a market cap of $1045.50 M.

In which sector does EyePoint Inc belong?

EyePoint Inc operates in the Biotechnology sector.

What documents are required to invest in EyePoint Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of EyePoint Inc?

The PE ratio of EyePoint Inc is N/A and the PB ratio is 4.60.